$8.17
0.080.99%
At Close: -
$8.10
-0.07-0.86%
After Hours: 6:35 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Adverum Biotechnologies (NASDAQ:ADVM) Stock, Analyst Ratings, Price Targets, Forecasts
Adverum Biotechnologies Inc has a consensus price target of $25.86 based on the ratings of 7 analysts. The high is $60 issued by Truist Securities on May 15, 2024. The low is $2 issued by RBC Capital on March 19, 2024. The 3 most-recent analyst ratings were released by Chardan Capital, Oppenheimer, and Truist Securities on July 18, 2024, June 25, 2024, and May 15, 2024, respectively. With an average price target of $41.67 between Chardan Capital, Oppenheimer, and Truist Securities, there's an implied 414.40% upside for Adverum Biotechnologies Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Chardan Capital
Oppenheimer
Truist Securities
HC Wainwright & Co.
Mizuho
1calculated from analyst ratings
Analyst Ratings for Adverum Biotechnologies
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/18/2024 | Buy Now | 393.83% | Chardan Capital | Daniil Gataulin | $4 → $40 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 208.64% | Oppenheimer | Francois Brisebois | → $25 | Initiates | → Outperform | Get Alert |
| 05/15/2024 | Buy Now | 640.74% | Truist Securities | Joon Lee | $60 → $60 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 270.37% | HC Wainwright & Co. | Matthew Caufield | → $30 | Reiterates | Buy → Buy | Get Alert |
| 04/30/2024 | Buy Now | 270.37% | HC Wainwright & Co. | Matthew Caufield | → $30 | Initiates | → Buy | Get Alert |
| 04/29/2024 | Buy Now | 171.6% | Mizuho | Graig Suvannavejh | $40 → $22 | Maintains | Buy | Get Alert |
| 03/19/2024 | Buy Now | -50.62% | Chardan Capital | Daniil Gataulin | → $40 | Reiterates | Buy → Buy | Get Alert |
| 03/19/2024 | Buy Now | -75.31% | RBC Capital | Luca Issi | $30 → $20 | Maintains | Sector Perform | Get Alert |
| 02/06/2024 | Buy Now | -50.62% | Mizuho | Graig Suvannavejh | $20 → $40 | Maintains | Buy | Get Alert |
| 11/02/2023 | Buy Now | -75.31% | Mizuho | Graig Suvannavejh | → $20 | Initiates | → Buy | Get Alert |
| 09/05/2023 | Buy Now | -25.93% | Truist Securities | Joon Lee | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | -50.62% | Chardan Capital | Daniil Gataulin | $20 → $40 | Upgrade | Neutral → Buy | Get Alert |
| 03/07/2023 | Buy Now | -75.31% | Ladenburg Thalmann | Aydin Huseynov | → $20 | Initiates | → Buy | Get Alert |
| 11/11/2022 | Buy Now | -75.31% | Chardan Capital | Daniil Gataulin | $25 → $20 | Maintains | Neutral | Get Alert |
| 11/11/2022 | Buy Now | -62.96% | RBC Capital | Luca Issi | $50 → $30 | Maintains | Sector Perform | Get Alert |
| 08/12/2022 | Buy Now | -69.14% | Chardan Capital | Daniil Gataulin | $30 → $25 | Maintains | Neutral | Get Alert |
| 07/07/2022 | Buy Now | -50.62% | Truist Securities | Joon Lee | $30 → $40 | Upgrade | Hold → Buy | Get Alert |
FAQ
What is the target price for Adverum Biotechnologies (ADVM) stock?
The latest price target for Adverum Biotechnologies (NASDAQ:ADVM) was reported by Chardan Capital on July 18, 2024. The analyst firm set a price target for $40.00 expecting ADVM to rise to within 12 months (a possible 393.83% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Adverum Biotechnologies (ADVM)?
The latest analyst rating for Adverum Biotechnologies (NASDAQ:ADVM) was provided by Chardan Capital, and Adverum Biotechnologies maintained their buy rating.
When was the last upgrade for Adverum Biotechnologies (ADVM)?
The last upgrade for Adverum Biotechnologies Inc happened on August 11, 2023 when Chardan Capital raised their price target to $4. Chardan Capital previously had a neutral for Adverum Biotechnologies Inc.
When was the last downgrade for Adverum Biotechnologies (ADVM)?
There is no last downgrade for Adverum Biotechnologies.
When is the next analyst rating going to be posted or updated for Adverum Biotechnologies (ADVM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adverum Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adverum Biotechnologies was filed on July 18, 2024 so you should expect the next rating to be made available sometime around July 18, 2025.
Is the Analyst Rating Adverum Biotechnologies (ADVM) correct?
While ratings are subjective and will change, the latest Adverum Biotechnologies (ADVM) rating was a maintained with a price target of $4.00 to $40.00. The current price Adverum Biotechnologies (ADVM) is trading at is $8.10, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.